Brief Clinical Report REDUCTION OF CENTRAL POSTSTROKE PAIN WITH THE SELECTIVE SEROTONIN REUPTAKE INHIBITOR FLUVOXAMINE

To investigate the effect of the selective serotonin reuptake inhibitor (SSRI) fluvoxamine on central poststroke pain (CPSP), fluvoxamine (25 to 125 mg daily) was given to 31 patients. Although 3 patients dropped out within 1 week, 28 patients who received fluvoxamine for 2 to 4 weeks showed a significant reduction in the visual analog scale (VAS) for pain from 7.7 - 2.2 to 6.0 - 3.4 (p <. 01). This improvement in VAS was significant in patients within less than 1 year after stroke, but not in those with a duration of more than 1 year. Zung s Self-rating Depression Scale (SDS) was also significantly improved after treatment, but there was no significant correlation between the changes in VAS and SDS. Although this is not a double-blind, placebo-controlled trial, these results suggest that fluvoxarnine is useful for the control of CPSP regardless of depression when used relatively early after stroke.

[1]  Irwin J. Kopin,et al.  The Biochemical Basis of Neuropharmacology , 1971, The Yale Journal of Biology and Medicine.

[2]  G. Gonzales.  Central pain , 1994, Neurology.

[3]  G. Leijon,et al.  Central post-stroke pain — a controlled trial of amitriptyline and carbamazepine , 1989, Pain.

[4]  G. Gebhart,et al.  Spinal pathways mediating tonic, coeruleospinal, and raphe-spinal descending inhibition in the rat. , 1987, Journal of neurophysiology.

[5]  Grethe Andersen,et al.  Incidence of central post-stroke pain , 1995, Pain.

[6]  F. Lenz,et al.  Central post-stroke pain: a challenge for the scientist and the clinician , 1995, Pain.

[7]  I. Egbunike,et al.  Antidepressants in the Management of Chronic Pain Syndromes , 1990, Pharmacotherapy.

[8]  D. Marazziti,et al.  Pain threshold is reduced in depression. , 1998, The international journal of neuropsychopharmacology.

[9]  P. Stokes,et al.  Risks and Benefits of Selective Serotonin Reuptake Inhibitors in the Treatment of Depression , 1998, Drug safety.

[10]  S. Schreiber,et al.  The antinociceptive effect of fluvoxamine , 1996, European Neuropsychopharmacology.

[11]  A. J. Smith,et al.  The analgesic effects of selective serotonin reuptake inhibitors , 1998, Journal of psychopharmacology.

[12]  P. Dayer,et al.  Central analgesic effects of desipramine, fluvoxamine, and moclobemide after single oral dosing: A study in healthy volunteers , 1993, Clinical pharmacology and therapeutics.

[13]  P. Tonin,et al.  Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. , 1996, Stroke.

[14]  J. King,et al.  Pain rehabilitation. 1. Basic science, acute pain, and neuropathic pain. , 1994, Archives of physical medicine and rehabilitation.

[15]  T. Nurmikko.  Mechanisms of Central Pain , 2000, The Clinical journal of pain.

[16]  Floyd E. Bloom,et al.  The biochemical basis of neuropharmacology, 8th ed. , 2003 .

[17]  M. Roberts,et al.  The effect of modification of 5-hydroxytryptamine function in nucleus raphe magnus on nociceptive threshold , 1984, Brain Research.